NIH Licenses Super Antibodies to Fight Cancer
Published Date: 7/14/2026
Notice
Summary
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NIH Antibodies Available for Licensing
The National Institute of Allergy and Infectious Diseases is offering government-owned pan anti-HLA monoclonal antibodies 3C10 and 15B1 for commercial licensing (HHS Ref. E-005-2026-0). A provisional patent application No. 64/053,946 was filed on April 30, 2026, and foreign patent applications have been filed on selected inventions to extend market coverage.
Pre-Clinical Antibodies Show Strong Activity
The pre-clinical antibodies 3C10 and 15B1 bind MHC-I at a different site than earlier antibodies (DX17 and W6/32), bind over 50 times more strongly, and activate human natural killer (NK) and T cells for tumor control. NIAID notes potential uses alone or with other immunotherapies (including CAR-T or CAR-NK) and possible application to chronic infections like TB, HIV, and hepatitis B or C.
Collaboration Opportunity and Contact
NIAID is seeking parties interested in collaborative research to further develop, evaluate, or commercialize this technology and requests statements of capability or interest. To get more information or access unpublished data you must contact Yogikala Prabhu (tel. 202-365-4785, email: Yogikala.Prabhu@nih.gov) and sign a Confidential Disclosure Agreement.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14003 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important research grant applications. These meetings keep sensitive info private, protecting ideas and personal details. Scientists applying for grants and the research community will feel the impact as funding decisions get made on time.
2026-14001 — National Human Genome Research Institute; Notice of Meeting
The National Human Genome Research Institute is holding a public meeting on September 28-29, 2026, to share updates and review grant applications. Scientists, researchers, and anyone interested in human genetics can join in person or online. This meeting helps decide which projects get funding, so it impacts future research and innovation in genetics.
2026-13802 — Government Owned Invention Available for License: Generating Conditional and Reverse Conditional Loss-of-Function Alleles in Mouse Casq2
The National Institutes of Health is offering special mouse strains that help study a rare heart rhythm disorder called CPVT. These mice let scientists explore how a key heart gene works and test new gene therapies. Researchers interested in this tool can access it now—no patents, just pure science ready to speed up discoveries!
2026-13612 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in late July 2026 to review and decide on important health research grant applications. These meetings keep sensitive info private to protect personal and commercial secrets. Researchers applying for grants and the public can expect no changes in funding timing or amounts, just careful, confidential reviews.
2026-13480 — Government Owned Invention Available for License: A Conserved Viral Peptide for Use in Cancer Immunotherapy
The National Cancer Institute has created a special viral peptide that could help prevent and treat a serious liver cancer called HCC. This new discovery might lead to a vaccine or therapy that boosts the immune system to fight cancer better. Researchers and companies interested in developing this treatment can now license the technology, opening doors for faster progress and potential health benefits worldwide.
2026-13479 — Government Owned Invention Available for License: Chimeric VLP Vaccines To Prevent HTLV-1 Infection
The National Cancer Institute has created a new vaccine to stop HTLV-1, a virus that can cause serious diseases like leukemia. Right now, no vaccine exists, so this invention could protect millions, especially in underserved areas. They’re looking for partners to help develop and license this promising vaccine, which could save lives and reduce healthcare costs in the near future.
Previous / Next Documents
Previous: 2026-14130 — Indian Gaming; Approval by Operation of Law of the Wyandotte Nation and State of Kansas Gaming Compact
The Wyandotte Nation and the State of Kansas now have an official gaming agreement that lets the tribe run class III gaming, including sports betting, starting July 14, 2026. Since the government didn’t act within 45 days, the deal automatically got approved by law. This means more gaming options and potential revenue for the tribe and the state, with sports bets placed anywhere in Kansas counting as if made on tribal land.
Next: 2026-14135 — David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.